## Answer
(model generated chain of thought explanation)

To determine which compound would best serve as a positive control for the experiment, we need to consider what is required to prevent mRNA degradation in the presence of D1 stimulation.

Firstly, we know that A1 and B1 receptors are involved in the regulation of dopamine release. When these receptors are stimulated, they can activate downstream signaling pathways that lead to the production of dopamine. However, if both A1 and B1 receptors are also stimulated at the same time, it would likely interfere with this process.

A positive control compound should be able to mimic or enhance D1 receptor stimulation without interfering with other receptor activities. Let's analyze each option:

A. Bromocriptine is a dopamine agonist that specifically stimulates D2 and D3 receptors, not D1. It would not be an effective positive control for this experiment.

B. Dobutamine is a beta-adrenergic agonist that primarily stimulates beta-1 receptors. While it may have some activity on other receptor types, its primary action is not selective for dopamine 1 receptors.

C. Epinephrine is a catecholamine that acts as a pure alpha-2 adrenergic agonist and has minimal to no effect on dopamine 1 or D1 receptors. It would not be an effective positive control for this experiment.

D. Fenoldopam is a dopamine receptor agonist that specifically stimulates D1 receptors, among other dopamine receptors. Its activity at D1 receptors would mimic the effects of D1 stimulation without interfering with A1 and B1 receptor activities, making it an ideal positive control compound for this experiment.

Therefore, the best answer is D.